Asia Executives On The Move: Senior Level Changes At Pfizer Upjohn, Simcere In China
The change of seasons sees a flurry of senior level executive changes taking place across the Asia Pacific health sector. Appointments include a new GM at Pfizer Upjohn China while Sanofi Japan has a new specialty business head and Lupin changes its US head.
You may also be interested in...
As the China immuno-oncology sector becomes increasingly crowded, CStone teams up with an innovative US business partner to go global.
During a recent press briefing, health officials in China disclosed the country is poised to reach an annual production capacity of 610 million doses for coronavirus vaccines. But they said prices must be based on manufacturing costs and not driven by supply and demand.
With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.